Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (250)	12/11/1997 10:23:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 328

Miljenko: I agree the drug is a solid improvement over Ampho B. I think (hope) the reduced toxicity will provide sufficient incentive for doctors to use it even though it will be more expensive. Here is another development: biz.yahoo.com They sound pretty confident that this will produce revenues: ''Revenues from our new technology products business unit will allow us to offset the cost of our own development needs by marketing unique products and unparalleled technologies to a variety of customers in the research field.'' said Patrick J. Mahaffy, president and CEO of NeXstar Pharmaceuticals. Peter